Emerging trends in oral delivery of peptide and protein drugs

Critical Reviews in Therapeutic Drug Carrier Systems

Volumn 20, Issue 2-3, 2003, Pages 153-214

  Mahato, Ram I ^a   Narang, Ajit S ^a   Thoma, Laura ^a   Miller, Duane D ^a  

^a UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

Author keywords

CYP3A4; Nanoparticles; Oral delivery; P glycoprotein; Permeation enhancers; Polymeric systems

Indexed keywords

BETA LACTAM ANTIBIOTIC; CHOLERA TOXIN; CYCLOSPORIN; CYCLOSPORIN A; DESMOPRESSIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENKEPHALIN[2 DEXTRO ALANINE 4 METHYLPHENYLALANINE 5 METHIONINOL SULFOXIDE]; ENZYME INHIBITOR; FG 120918; GAMMA BUTYROLACTONE GAMMA CARBONYLHISTIDYLPROLINAMIDE CITRATE; LAURIC ACID; METENKEPHALIN; METKEPHAMID; NIFALATIDE; PENTAPEPTIDE; PEPTIDE; POLYMER; PROTEIN; PROTEIN INHIBITOR; PROTIRELIN; PROTIRELIN[3 (3,3 DIMETHYLPROLINAMIDE)]; PYRO 2 AMINOADIPYLHISTIDYLTHIAZOLIDINE 4 CARBOXAMIDE; RIFAMPICIN; THYROTROPIN; UNCLASSIFIED DRUG; UNINDEXED DRUG; VALSPODAR; VASOPRESSIN; VERAPAMIL; ZONULA OCCLUDENS TOXIN; ZOSUQUIDAR;

DIABETES INSIPIDUS; DRUG BIOAVAILABILITY; DRUG DELIVERY SYSTEM; DRUG FORMULATION; DRUG STABILITY; HUMAN; HYDROPHOBICITY; MACROMOLECULE; MOLECULAR WEIGHT; NONHUMAN; PROTEIN DEGRADATION; PROTEIN MODIFICATION; PROTEIN TRANSPORT; REVIEW; STOMACH PH;

ADMINISTRATION, ORAL; ANIMALS; DRUG DELIVERY SYSTEMS; HUMANS; INTESTINAL ABSORPTION; MODELS, BIOLOGICAL; PEPTIDES; PROTEINS;

EID: 0141997761     PISSN: 07434863     EISSN: None     Source Type: Journal    
DOI: 10.1615/CritRevTherDrugCarrierSyst.v20.i23.30     Document Type: Review

References (238)

1. Saffran M, Pansky B, Budd GC, Williams FE. Insulin and the gastrointestinal tract. J Control Release 1997; 46(1-2):89-98.
2. Saffran M, Kumar GS, Savariar C, Burnham JC, Williams F, Neckers DC. A new approach to the oral administration of insulin and other peptide drugs. Science 1986; 233(4768):1081-4.
3. Fix JA. Oral controlled release technology for peptides: status and future prospects. Pharm Res 1996; 13(12):1760-4.
4. Drewe J, Fricker G, Vonderscher J, Beglinger C. Enteral absorption of octreotide: absorption enhancement by polyoxyethylene-24-cholesterol ether. Br J Pharmacol 1993; 108(2):298-303.
5. Adjei A, Love S, Johnson E, Diaz G, Greer J, Haviv F, et al. Effect of formulation adjuvants on gastrointestinal absorption of leuprolide acetate. J Drug Target 1993; 1(3):251-8.
6. Okada H, Yamazaki I, Ogawa Y, Hirai S, Yashiki T, Mima H. Vaginal absorption of a potent luteinizing hormone-releasing hormone analog (leuprolide) in rats. I: Absorption by various routes and absorption enhancement. J Pharm Sci 1982; 71(12):1367-71.
7. Yodoya E, Uemura K, Tenma T, Fujita T, Murakami M, Yamamoto A, et al. Enhanced permeability of tetragastrin across the rat intestinal membrane and its reduced degradation by acylation with various fatty acids. J Pharmacol Exp Ther 1994; 271(3):1509-13.
8. Ingemann M, Frokjaer S, Hovgaard L, Bronsted H. Peptide and protein drug delivery systems for non-parenteral routes of administration. In: Frokjaer S, Hovgaard L, editors. Pharmaceutical Formulation Development of Peptides and Proteins. London: Taylor and Francis, 2000, 189-205.
9. Li AP. Screening for human ADME/Tox drug properties in drug discovery. Drug Discov Today 2001; 6(7):357-366.
10. Leone-Bay A, Sato M, Paton D, Hunt AH, Sarubbi D, Carozza M, et al. Oral delivery of biologically active parathyroid hormone. Pharm Res 2001; 18(7):964-70.
11. Tortora GJ, Garabowski SR. Principles of Anatomy and Physiology. 8 ed. New York: Harper Collins, 1996.
12. Bai JP, Amidon GL. Structural specificity of mucosal-cell transport and metabolism of peptide drugs: implication for oral peptide drug delivery. Pharm Res 1992; 9(8):969-78.
13. Taylor DC, Leahy DE. In: Hardy JG, Wilson CG, editors. Drug Delivery to the Gastrointestinal Tract. Chichester, UK: Ellis Horwood, 1989, 133-145.
14. el Tayar N, Mark AE, Vallat P, Brunne RM, Testa B, van Gunsteren WF. Solvent-dependent conformation and hydrogen-bonding capacity of cyclosporin A: evidence from partition coefficients and molecular dynamics simulations. J Med Chem 1993; 36(24):3757-64.
15. Conradi RA, Hilgers AR, Ho NF, Burton PS. The influence of peptide structure on transport across Caco-2 cells. Pharm Res 1991; 8(12):1453-60.
16. Conradi RA, Hilgers AR, Ho NF, Burton PS. The influence of peptide structure on transport across Caco-2 cells. II. Peptide bond modification which results in improved permeability. Pharm Res 1992; 9(3):435-9.
17. Burton PS, Conradi RA, Ho NF, Hilgers AR, Borchardt RT. How structural features influence the biomembrane permeability of peptides. J Pharm Sci 1996; 85(12):1336-40.
18. Powell DW. Barrier function of epithelia. Am J Physiol 1981; 241(4):G275-88.
19. Karls MS, Rush BD, Wilkinson KF, Vidmar TJ, Burton PS, Ruwart MJ. Desolvation energy: a major determinant of absorption, but not clearance, of peptides in rats. Pharm Res 1991; 8(12):1477-81.
20. Kim DC, Burton PS, Borchardt RT. A correlation between the permeability characteristics of a series of peptides using an in vitro cell culture model (Caco-2) and those using an in situ perfused rat ileum model of the intestinal mucosa. Pharm Res 1993; 10(12):1710-4.
21. Stenberg P, Luthman K, Artursson P. Prediction of membrane permeability to peptides from calculated dynamic molecular surface properties. Pharm Res 1999; 16(2):205-12.
22. Pauletti GM, Okumu FW, Borchardt RT. Effect of size and charge on the passive diffusion of peptides across Caco-2 cell monolayers via the paracellular pathway. Pharm Res 1997; 14(2):164-8.
23. Cox DS, Raje S, Gao H, Salami NN, Eddington ND. Enhanced permeability of molecular weight markers and poorly bioavailable compounds across Caco-2 cell monolayers using the absorption enhancer, zonula occludens toxin. Pharm Res 2002; 19(11):1680-8.
24. Pappenheimer JR, Reiss KZ. Contribution of solvent drag through intercellular junctions to absorption of nutrients by the small intestine of the rat. J Membr Biol 1987; 100(2):123-36.
25. Sawada T, Tomita M, Hayashi M, Awazu S. Paracellular channel characterized by non-electrolyte permeation through the colonic membrane of the rat. J Pharmacobiodyn 1989; 12(10):634-9.
26. Hosoya K, Kubo H, Natsume H, Sugibayashi K, Morimoto Y, Yamashita S. The structural barrier of absorptive mucosae: site difference of the permeability of fluorescein isothiocyanate-labelled dextran in rabbits. Biopharm Drug Dispos 1993; 14(8):685-95.
27. Pappenheimer JR. Paracellular intestinal absorption of glucose, creatinine, and mannitol in normal animals: relation to body size. Am J Physiol 1990; 259(2 Pt 1):G290-9.
28. Fasano A, Uzzau S. Modulation of intestinal tight junctions by Zonula occludens toxin permits enteral administration of insulin and other macromolecules in an animal model. J Clin Invest 1997; 99(6):1158-64.
29. Fasano A, Fiorentini C, Donelli G, Uzzau S, Kaper JB, Margaretten K, et al. Zonula occludens toxin modulates tight junctions through protein kinase C-dependent actin reorganization, in vitro. J Clin Invest 1995; 96(2):710-20.
30. Fasano A. Regulation of intercellular tight junctions by zonula occludens toxin and its eukaryotic analogue zonulin. Ann NY Acad Sci 2000; 915:214-22.
31. Madara JL. Regulation of the movement of solutes across tight junctions. Annu Rev Physiol 1998; 60:143-59.
32. Hugger ED, Audus KL, Borchardt RT. Effects of poly(ethylene glycol) on efflux transporter activity in Caco-2 cell monolayers. J Pharm Sci 2002; 91(9):1980-90.
33. Quan YS, Fujita T, Tohara D, Tsuji M, Kohyama M, Yamamoto A. Transport kinetics of leucine enkephalin across Caco-2 monolayers: quantitative analysis for contribution of enzymatic and transport barrier. Life Sci 1999; 64(14):1243-52.
34. Artursson P, Karlsson J. Correlation between oral drug absorption in humans and apparent drug permeability coefficients in human intestinal epithelial (Caco-2) cells. Biochem Biophys Res Commun 1991; 175(3):880-5.
35. Fernandez-Lopez JA, Casado J, Argiles JM, Alemany M. In the rat, intestinal lymph carries a significant amount of ingested glucose into the bloodstream. Arch Int Physiol Biochim Biophys 1992; 100(3):231-6.
36. Charman WN, Stella, V.J. Estimating the maximum potential for intestinal lymphatic transport of lipophilic drug molecules. Int J Pharm 1986; 34:175-178.
37. Caliph SM, Charman WN, Porter CJ. Effect of short-, medium-, and long-chain fatty acid-based vehicles on the absolute oral bioavailability and intestinal lymphatic transport of halofantrine and assessment of mass balance in lymph-cannulated and non-cannulated rats. J Pharm Sci 2000; 89(8):1073-84.
38. O'Driscoll CM. Lipid-based formulations for intestinal lymphatic delivery. Eur J Pharm Sci 2002; 15(5):405-15.
39. Granger DN, Mortillaro NA, Kvietys PR, Rutili G, Parker JC, Taylor AE. Role of the interstitial matrix during intestinal volume absorption. Am J Physiol 1980; 238(3): G183-9.
40. Westrom BR, Svendsen J, Ohlsson BG, Tagesson C, Karlsson BW. Intestinal transmission of macromolecules (BSA and FITC-labelled dextrans) in the neonatal pig. Influence of age of piglet and molecular weight of markers. Biol Neonate 1984; 46(1):20-6.
41. Westrom B, Svendsen J, Tagesson C. Intestinal permeability to polyethyleneglycol 600 in relation to macromolecular 'closure' in the neonatal pig. Gut 1984; 25(5):520-5.
42. Udall JN, Colony P, Fritze L, Pang K, Trier JS, Walker WA. Development of gastrointestinal mucosal barrier. II. The effect of natural versus artificial feeding on intestinal permeability to macromolecules. Pediatr Res 1981; 15(3):245-9.
43. Ekstrom GM, Westrom BR. Intestinal uptake and transmission of macromolecules into the blood in the young guinea pig. J Pediatr Gastroenterol Nutr 1992; 14(1):71-8.
44. Telemo E, Westrom BR, Ekstrom G, Karlsson BW. Intestinal macromolecular transmission in the young rat: influence of protease inhibitors during development. Biol Neonate 1987; 52(3):141-8.
45. Udall JN, Bloch KJ, Vachino G, Feldman P, Walker WA. Development of the gastrointestinal mucosal barrier. IV. The effect of inhibition of proteolysis on the uptake of macromolecules by the intestine of the newborn rabbit before and after weaning. Biol Neonate 1984; 45(6):289-95.
46. Brader ML, Sukumar M, Pekar AH, McClellan DS, Chance RE, Flora DB, et al. Hybrid insulin cocrystals for controlled release delivery. Nat Biotechnol 2002; 20(8):800-4.
47. Lee VHL. Protein and Peptide Drug Delivery. New York: Marcel Dekker, 1991.
48. Woodley JF. Enzymatic barriers for GI peptide and protein delivery. Crit Rev Ther Drug Carrier Syst 1994; 11(2-3):61-95.
49. Bernkop-Schnurch A, Walker G. Multifunctional matrices for oral peptide delivery. Crit Rev Ther Drug Carrier Syst 2001; 18(5):459-501.
50. Barthe L, Woodley J, Houin G. Gastrointestinal absorption of drugs: methods and studies. Fundam Clin Pharmacol 1999; 13(2):154-68.
51. Silk DB, Nicholson JA, Kim YS. Relationships between mucosal hydrolysis and transport of two phenylalanine dipeptides. Gut 1976; 17(11):870-6.
52. Heizer WD, Kerley RL, Isselbacher KJ. Intestinal peptide hydrolases differences between brush border and cytoplasmic enzymes. Biochim Biophys Acta 1972; 264(3):450-61.
53. Kim YS, Birtwhistle W, Kim YW. Peptide hydrolases in the brush border and soluble fractions of small intestinal mucosa of rat and man. J Clin Invest 1972; 51(6):1419-30.
54. Langguth P, Merkle HP, Amidon GL. Oral absorption of peptides: the effect of absorption site and enzyme inhibition on the systemic availability of metkephamid. Pharm Res 1994; 11(4):528-35.
55. Sterchi EE, Woodley JF. Peptide hydrolases of the human small intestinal mucosa: distribution of activities between brush border membranes and cytosol. Clin Chim Acta 1980; 102(1):49-56.
56. Ledger R, Tucker IG, Walker GF. The metabolic barrier of the lower intestinal tract of salmon to the oral delivery of protein and peptide drugs. J Control Release 2002; 85(1-3):91-103.
57. Gottesman MM, Pastan I. Biochemistry of multidrug resistance mediated by the multidrug transporter. Annu Rev Biochem 1993; 62:385-427.
58. Lin JH, Yamazaki M. Role of P-glycoprotein in pharmacokinetics: clinical implications. Clin Pharmacokinet 2003; 42(1):59-98.
59. Creamer B. The turnover of the epithelium of the small intestine. Br Med Bull 1967; 23(3):226-30.
60. Burton PS, Conradi RA, Hilgers AR, Ho NF. Evidence for a polarized efflux system for peptides in the apical membrane of Caco-2 cells. Biochem Biophys Res Commun 1993; 190(3):760-6.
61. Saeki T, Ueda K, Tanigawara Y, Hori R, Komano T. Human P-glycoprotein transports cyclosporin A and FK506. J Biol Chem 1993; 268(9):6077-80.
62. Augustijns PF, Bradshaw TP, Gan LS, Hendren RW, Thakker DR. Evidence for a polarized efflux system in CACO-2 cells capable of modulating cyclosporin A transport. Biochem Biophys Res Commun 1993; 197(2):360-5.
63. Hebert MF, Roberts JP, Prueksaritanont T, Benet LZ. Bioavailability of cyclosporine with concomitant rifampin administration is markedly less than predicted by hepatic enzyme induction. Clin Pharmacol Ther 1992; 52(5):453-7.
64. van Asperen J, van Tellingen O, Sparreboom A, Schinkel AH, Borst P, Nooijen WJ, et al. Enhanced oral bioavailability of paclitaxel in mice treated with the P-glycoprotein blocker SDZ PSC 833. Br J Cancer 1997; 76(9):1181-3.
65. Thummel KE, Wilkinson GR. In vitro and in vivo drug interactions involving human CYP3A. Annu Rev Pharmacol Toxicol 1998; 38:389-430.
66. Kolars JC, Lown KS, Schmicdlin-Ren P, Ghosh M, Fang C, Wrighton SA, et al. CYP3A gene expression in human gut epithelium. Pharmacogenetics 1994; 4(5):247-59.
67. Hunter J, Hirst BH. Intestinal secretion of drugs. The role of P-glycoprotein and related efflux systems in limiting oral drug absorption. Adv Drug Deliv Rev 1997; 25:129-157.
68. Wacher VJ, Wu CY, Benet LZ. Overlapping substrate specificities and tissue distribution of cytochrome P450 3A and P-glycoprotein: implications for drug delivery and activity in cancer chemotherapy. Mol Carcinog 1995; 13(3):129-34.
69. Campana C, Regazzi MB, Buggia I, Molinaro M. Clinically significant drug interactions with cyclosporin. An update. Clin Pharmacokinet 1996; 30(2):141-79.
70. Lang VB, Langguth P, Ottiger C, Wunderli-Allenspach H, Rognan D, Rothen-Rutishauser B, et al. Structure-permeation relations of met-enkephalin peptide analogues on absorption and secretion mechanisms in Caco-2 monolayers. J Pharm Sci 1997; 86(7):846-53.
71. Mozhaev VV, Siksnis VA, Melik-Nubarov NS, Galkantaite NZ, Denis GJ, Butkus EP, et al. Protein stabilization via hydrophilization. Covalent modification of trypsin and alpha-chymotrypsin. Eur J Biochem 1988; 173(1):147-54.
72. Barbaric S, Leustek I, Pavlovic B, Cesi V, Mildner P. Stabilization of glycoenzymes by cross-linking of their carbohydrate chains. Ann NY Acad Sci 1988; 542:173-9.
73. Krondahl E, Orzechowski A, Ekstrom G, Lennernas H. Rat jejunal permeability and metabolism of mu-selective tetrapeptides in gastrointestinal fluids from humans and rats. Pharm Res 1997; 14(12):1780-5.
74. Kashi SD, Lee VH. Enkephalin hydrolysis in homogenates of various absorptive mucosae of the albino rabbit: similarities in rates and involvement of aminopeptidases. Life Sci 1986; 38(22):2019-28.
75. Roemer D, Buescher HH, Hill RC, Pless J, Bauer W, Cardinaux F, et al. A synthetic enkephalin analogue with prolonged parenteral and oral analgesic activity. Nature 1977; 268(5620):547-9.
76. Su KS, Campanale KM, Mendelsohn LG, Kerchner GA, Gries CL. Nasal delivery of polypeptides I: nasal absorption of enkephalins in rats. J Pharm Sci 1985; 74(4):394-8.
77. Berschneider HM, Martens H, Powell DW. Effect of BW 942C, an enkephalinlike pentapeptide, on sodium and chloride transport in the rabbit ileum. Gastroenterology 1988; 94(1):127-36.
78. Mierke DF, Said-Nejad OE, Schiller PW, Goodman M. Enkephalin analogues containing beta-naphthylalanine at the fourth position. Biopolymers 1990; 29(1):179-96.
79. Posner J, Dean K, Jeal S, Moody SG, Peck AW, Rutter G, et al. A preliminary study of the pharmacodynamics and pharmacokinetics of a novel enkephalin analogue [Tyr-D.Arg-Gly-Phe (4NO2).Pro.NH2 (BW443C)] in healthy volunteers. Eur J Clin Pharmacol 1988; 34(1):67-71.
80. Mitsuma T, Nogimori T. Influence of the route of administration on thyrotropin-releasing hormone concentration in the mouse brain. Experientia 1983; 39(6):620-2.
81. Yokohama S, Yamashita K, Toguchi H, Takeuchi J, Kitamori N. Absorption of thyrotropin-releasing hormone after oral administration of TRH tartrate monohydrate in the rat, dog and human. J Pharmacobiodyn 1984; 7(2):101-11.
82. Yokohama S, Yoshioka T, Yamashita K, Kitamori N. Intestinal absorption mechanisms of thyrotropin-releasing hormone. J Pharmacobiodyn 1984; 7(7):445-51.
83. Hichens M. A comparison of thyrotropin-releasing hormone with analogs: influence of disposition upon pharmacology. Drug Metab Rev 1983; 14(1):77-98.
84. Spatola AF, Lankiewicz L, Labroo VM, Vonhof S. Thionated analogues of thyrotropin releasing hormone. US patent 5,244,884. 1993.
85. Tache Y, Goto Y, Lauffenburger M, Lesiege D. Potent central nervous system action of p-Glu-His-(3,3′-dimethyl)-Pro NH2, a stabilized analog of TRH, to stimulate gastric secretion in rats. Regul Pept 1984; 8(1):71-8.
86. Yokohama S, Yoshioka T, Kitamori N. Absorption of gamma-butyrolactone-gamma-carbonyl-L-histidyl-L-prolinamide citrate (DN-1417), an analog of thyrotropin-releasing hormone, in rats and dogs. J Pharmacobiodyn 1984; 7(8):527-35.
87. Yokohama S, Yoshioka T, Kitamori N, Shimamoto T, Kamada A. Intestinal absorption mechanisms of gamma-butyrolactone-gamma-carbonyl-L-histidyl-L-prolinamide citrate (DN-1417) and thyrotropin-releasing hormone (TRH). J Pharmacobiodyn 1985; 8(4):278-85.
88. Rado JP, Marosi J, Szende L, Borbely L, Tako J, Fischer J. The antidiuretic action of 1-deamino-8-D-arginine vasopressin (DDAVP) in man. Int J Clin Pharmacol Biopharm 1976; 13(3):199-209.
89. Vavra I, Machova A, Krejci I. Antidiuretic action of 1-deamino-(8-D-arginine)-vasopressin in unanesthetized rats. J Pharmacol Exp Ther 1974; 188(1):241-7.
90. Sawyer WH, Acosta M, Manning M. Structural changes in the arginine vasopressin molecule that prolong its antidiuretic action. Endocrinology 1974; 95(1):140-9.
91. Vilhardt H, Lundin S. In vitro intestinal transport of vasopressin and its analogues. Acta Physiol Scand 1986; 126(4):601-7.
92. Lundin S, Vilhardt H. Absorption of 1-deamino-8-D-arginine vasopressin from different regions of the gastrointestinal tract in rabbits. Acta Endocrinol (Copenhagen) 1986; 112(3):457-60.
93. Vilhardt H, Bie P. Antidiuretic effect of perorally administered DDAVP in hydrated humans. Acta Endocrinol (Copenhagen) 1984; 105(4):474-6.
94. Williams TD, Dunger DB, Lyon CC, Lewis RJ, Taylor F, Lightman SL. Antidiuretic effect and pharmacokinetics of oral 1-desamino-8-D-arginine vasopressin. 1. Studies in adults and children. J Clin Endocrinol Metab 1986; 63(1):129-32.
95. Cunnah D, Ross G, Besser GM. Management of cranial diabetes insipidus with oral desmopressin (DDAVP). Clin Endocrinol (Oxford) 1986; 24(3):253-7.
96. Yamada K, Murakami M, Yamamoto A, Takada K, Muranishi S. Improvement of intestinal absorption of thyrotropin-releasing hormone by chemical modification with lauric acid. J Pharm Pharmacol 1992; 44(9):717-21.
97. Tanaka K, Fujita T, Yamamoto Y, Murakami M, Yamamoto A, Muranishi S. Enhancement of intestinal transport of thyrotropin-releasing hormone via a carrier-mediated transport system by chemical modification with lauric acid. Biochim Biophys Acta 1996; 1283(1):119-26.
98. Bundgaard H, Moss J. Prodrug derivatives of thyrotropin-releasing hormone (TRH). US patent 5,405,834. 1995.
99. Hashimoto M, Takada K, Kiso Y, Muranishi S. Synthesis of palmitoyl derivatives of insulin and their biological activities. Pharm Res 1989; 6(2):171-6.
100. Myers SR, Yakubu-Madus FE, Johnson WT, Baker JE, Cusick TS, Williams VK, et al. Acylation of human insulin with palmitic acid extends the time action of human insulin in diabetic dogs. Diabetes 1997; 46(4):637-42.
101. Hoffman A, Ziv E. Pharmacokinetic considerations of new insulin formulations and routes of administration. Clin Pharmacokinet 1997; 33(4):285-301.
102. Kipnes M, Dandona P, Tripathy D, Still JG, Kosutic G. Control of postprandial plasma glucose by an oral insulin product (HIM2) in patients with type 2 diabetes. Diabetes Care 2003; 26(2):421-6.
103. Clement S, Still JG, Kosutic G, McAllister RG. Oral insulin product hexyl-insulin monoconjugate 2 (HIM2) in type 1 diabetes mellitus: the glucose stabilization effects of HIM2. Diabetes Technol Ther 2002; 4(4):459-66.
104. White DJ. Cyclosporin A. Clinical pharmacology and therapeutic potential. Drugs 1982; 24(4):322-34.
105. Cefalu WT, Pardridge WM. Restrictive transport of a lipid-soluble peptide (cyclosporin) through the blood-brain barrier. J Neurochem 1985; 45(6):1954-6.
106. Reymond JP, Steimer JL, Niederberger W. On the dose dependency of cyclosporin A absorption and disposition in healthy volunteers. J Pharmacokinet Biopharm 1988; 16(4):331-53.
107. Grevel J. Absorption of cyclosporine A after oral dosing. Transplant Proc 1986; 18(6 Suppl 5):9-15.
108. Wagner O, Schreier E, Heitz F, Maurer G. Tissue distribution, disposition, and metabolism of cyclosporine in rats. Drug Metab Dispos 1987; 15(3):377-83.
109. Tarr BD, Yalkowsky SH. Enhanced intestinal absorption of cyclosporine in rats through the reduction of emulsion droplet size. Pharm Res 1989; 6(1):40-3.
110. Drewe J, Beglinger C, Kissel T. The absorption site of cyclosporin in the human gastrointestinal tract. Br J Clin Pharmacol 1992; 33(1):39-43.
111. Sawchuk RJ, Awni WM. Absorption of cyclosporine from rabbit small intestine in situ. J Pharm Sci 1986; 75(12):1151-6.
112. Whitington PF, Emond JC, Whitington SH, Broelsch CE, Baker AL. Small-bowel length and the dose of cyclosporine in children after liver transplantation. N Engl J Med 1990; 322(11):733-8.
113. Grevel J, Nuesch E, Abisch E, Kutz K. Pharmacokinetics of oral cyclosporin A (Sandimmun) in healthy subjects. Eur J Clin Pharmacol 1986; 31(2):211-6.
114. Ogino Y, Kobayashi E, Kita J, Fujimura A, Kogure H. The site of absorption of cyclosporin A in the small intestine of the rat: a preliminary report. Transplant Proc 1999; 31(6):2659-60.
115. Keogh A, Day R, Critchley L, Duggin G, Baron D. The effect of food and cholestyramine on the absorption of cyclosporine in cardiac transplant recipients. Transplant Proc 1988; 20(1):27-30.
116. Elzinga LW, Bennett WM, Barry JM. The effect of dimethyl sulfoxide on the absorption of cyclosporine in rats. Transplantation 1989; 47(2):394-5.
117. Kahan BD, Kramer WG, Wideman C, Flechner SM, Lorber MI, Van Buren CT. Demographic factors affecting the pharmacokinetics of cyclosporine estimated by radioimmunoassay. Transplantation 1986; 41(4):459-64.
118. Ritschel WA, Ritschel GB, Sabouni A, Wolochuk D, Schroeder T. Study on the peroral absorption of the endekapeptide cyclosporine A. Methods Find Exp Clin Pharmacol 1989; 11(4):281-7.
119. Ptachcinski RJ, Venkataramanan R, Rosenthal JT, Burckart GJ, Taylor RJ, Hakala TR. The effect of food on cyclosporine absorption. Transplantation 1985; 40(2):174-6.
120. Lowman AM, Morishita M, Kajita M, Nagai T, Peppas NA. Oral delivery of insulin using pH-responsive complexation gels. J Pharm Sci 1999; 88(9):933-7.
121. Kang SI, Bae YH. pH-induced solubility transition of sulfonamide-based polymers. J Control Release 2002; 80(1-3):145-55.
122. Kyriakides TR, Cheung CY, Murthy N, Bornstein P, Stayton PS, Hoffman AS. pH-sensitive polymers that enhance intracellular drug delivery in vivo. J Control Release 2002; 78(1-3):295-303.
123. Watnasirichaikul S, Davies NM, Rades T, Tucker IG. Preparation of biodegradable insulin nanocapsules from biocompatible microemulsions. Pharm Res 2000; 17(6):684-9.
124. Watnasirichaikul S, Rades T, Tucker IG, Davies NM. In-vitro release and oral bioactivity of insulin in diabetic rats using nanocapsules dispersed in biocompatible microemulsion. J Pharm Pharmacol 2002; 54(4):473-80.
125. Bernkop-Schnurch A. The use of inhibitory agents to overcome the enzymatic barrier to perorally administered therapeutic peptides and proteins. J Control Release 1998; 52(1-2):1-16.
126. Tozaki H, Emi Y, Horisaka E, Fujita T, Yamamoto A, Muranishi S. Degradation of insulin and calcitonin and their protection by various protease inhibitors in rat caecal contents: implications in peptide delivery to the colon. J Pharm Pharmacol 1997; 49(2):164-8.
127. Fujii S, Yokoyama T, Ikegaya K, Sato F, Yokoo N. Promoting effect of the new chymotrypsin inhibitor FK-448 on the intestinal absorption of insulin in rats and dogs. J Pharm Pharmacol 1985; 37(8):545-9.
128. Shinomiya M, Shirai K, Saito Y, Yoshida S, Matsuoka N. Effect of new chymotrypsin inhibitor (FK-448) on intestinal absorption of insulin. Lancet 1985; 1(8437):1092-3.
129. Lee HJ, Amidon GL. The effect of enzyme inhibitor and absorption site following [D-ala2, D-leu5]enkephalin oral administration in rats. Biopharm Drug Dispos 2002; 23(4):131-41.
130. Sood A, Panchagnula R. Peroral route: an opportunity for protein and peptide drug delivery. Chem Rev 2001; 101(11):3275-303.
131. Nakada Y, Awata N, Nakamichi C, Sugimoto I. The effect of additives on the oral mucosal absorption of human calcitonin in rats. J Pharmacobiodyn 1988; 11(6):395-401.
132. Stoll BR, Leipold HR, Milstein S, Edwards DA. A mechanistic analysis of carrier-mediated oral delivery of protein therapeutics. J Control Release 2000; 64(1-3):217-28.
133. Leone-Bay A, Ho KK, Agarwal R, Baughman RA, Chaudhary K, DeMorin F, et al. 4-[4-[(2-Hydroxybenzoyl)amino]phenyl]butyric acid as a novel oral delivery agent for recombinant human growth hormone. J Med Chem 1996; 39(13):2571-8.
134. Leone-Bay A, Paton DR, Weidner JJ. The development of delivery agents that facilitate the oral absorption of macromolecular drugs. Med Res Rev 2000; 20(2):169-86.
135. Leone-Bay A, Santiago N, Achan D, Chaudhary K, DeMorin F, Falzarano L, et al. N-acylated alpha-amino acids as novel oral delivery agents for proteins. J Med Chem 1995; 38(21):4263-9.
136. Milstein SJ, Leipold H, Sarubbi D, Leone-Bay A, Mlynek GM, Robinson JR, et al. Partially unfolded proteins efficiently penetrate cell membranes-implications for oral drug delivery. J Control Release 1998; 53(1-3):259-67.
137. Schatz G, Dobberstein B. Common principles of protein translocation across membranes. Science 1996; 271(5255):1519-26.
138. Wu SJ, Robinson JR. Transport of human growth hormone across Caco-2 cells with novel delivery agents: evidence for P-glycoprotein involvement. J Control Release 1999; 62(1-2):171-7.
139. Goldberg M, Gomez-Orellana I. Challenges for the oral delivery of macromolecules. Nat Rev Drug Discov 2003; 2(4):289-95.
140. Grass GM, Morehead WT. Evidence for site-specific absorption of a novel ACE inhibitor. Pharm Res 1989; 6(9):759-65.
141. Friedman DI, Amidon GL. Passive and carrier-mediated intestinal absorption components of two angiotensin converting enzyme (ACE) inhibitor prodrugs in rats: enalapril and fosinopril. Pharm Res 1989; 6(12):1043-7.
142. Zheng Y, Qiu Y, Lu MF, Hoffman D, Reiland TL. Permeability and absorption of leuprolide from various intestinal regions in rabbits and rats. Int J Pharm 1999; 185(1):83-92.
143. Lu RH, Kopeckova P, Kopecek J. Degradation and aggregation of human calcitonin in vitro. Pharm Res 1999; 16(3):359-67.
144. Leitch GJ. Regional variations in the composition of purified brush borders isolated from infant and adult rabbit small intestine. Arch Int Physiol Biochim 1971; 79(2):279-86.
145. Triadou N, Bataille J, Schmitz J. Longitudinal study of the human intestinal brush border membrane proteins. Distribution of the main disaccharidases and peptidases. Gastroenterology 1983; 85(6):1326-32.
146. Miura S, Song IS, Morita A, Erickson RH, Kim YS. Distribution and biosynthesis of aminopeptidase N and dipeptidyl aminopeptidase IV in rat small intestine. Biochim Biophys Acta 1983; 761(1):66-75.
147. Vaeth GF, Henning SJ. Postnatal development of peptidase enzymes in rat small intestine. J Pediatr Gastroenterol Nutr 1982; 1(1):111-7.
148. Asatoor AM, Chadha A, Milne MD, Prosser DI. Intestinal absorption of stereoisomers of dipeptides in the rat. Clin Sci Mol Med Suppl 1973; 42(2):199-212.
149. Frizzell RA, Schultz SG. Ionic conductances of extracellular shunt pathway in rabbit ileum. Influence of shunt on transmural sodium transport and electrical potential differences. J Gen Physiol 1972; 59(3):318-46.
150. Grass GM, Sweetana SA. In vitro measurement of gastrointestinal tissue permeability using a new diffusion cell. Pharm Res 1988; 5(6):372-6.
151. Thomson AB, Weinstein WM. Transport kinetics of D-glucose in human small intestinal mucosa: rate constants in histologically normal and abnormal mucosal biopsies. Dig Dis Sci 1979; 24(6):442-8.
152. Grass GM, Sweetana SA, Bozarth CA. The effects of enprostil and RS-86505-007 on in-vitro intestinal permeability of rabbit and monkey. J Pharm Pharmacol 1990; 42(1):40-4.
153. Youngberg CA, Wlodyga J, Schmaltz S, Dressman JB. Radiotelemetric determination of gastrointestinal pH in four healthy beagles. Am J Vet Res 1985; 46(7):1516-21.
154. Lui CY, Amidon GL, Berardi RR, Fleisher D, Youngberg C, Dressman JB. Comparison of gastrointestinal pH in dogs and humans: implications on the use of the beagle dog as a model for oral absorption in humans. J Pharm Sci 1986; 75(3):271-4.
155. Chadwick VS, Phillips SF, Hofmann AF. Measurements of intestinal permeability using low molecular weight polyethylene glycols (PEG 400). I. Chemical analysis and biological properties of PEG 400. Gastroenterology 1977; 73(2):241-6.
156. Chadwick VS, Phillips SF, Hofmann AF. Measurements of intestinal permeability using low molecular weight polyethylene glycols (PEG 400). II. Application to normal and abnormal permeability states in man and animals. Gastroenterology 1977; 73(2):247-51.
157. Ma TY, Hollander D, Krugliak P, Katz K. PEG 400, a hydrophilic molecular probe for measuring intestinal permeability. Gastroenterology 1990; 98(1):39-46.
158. Ho NF. Utilizing bile acid carrier mechanisms to enhance liver and small intestine absorption. Ann NY Acad Sci 1987; 507:315-29.
159. Donaldson RM. Intrinsic factor and the transport of cobalamin. In: Jonsson LR, editor. Physiology of the Gastrointestinal Tract. New York: Raven Press, 1987, 959-973.
160. Pappenheimer JR, Dahl CE, Karnovsky ML, Maggio JE. Intestinal absorption and excretion of octapeptides composed of D amino acids. Proc Natl Acad Sci USA 1994; 91(5):1942-5.
161. Ramanujam KS, Seetharam S, Ramasamy M, Seetharam B. Expression of cobalamin transport proteins and cobalamin transcytosis by colon adenocarcinoma cells. Am J Physiol 1991; 260(3 Pt 1):G416-22.
162. Dix CJ, Hassan IF, Obray HY, Shah R, Wilson G. The transport of vitamin B12 through polarized monolayers of Caco-2 cells. Gastroenterology 1990; 98(5 Pt 1):1272-9.
163. Robertson JA, Gallagher ND. In vivo evidence that cobalamin is absorbed by receptor-mediated endocytosis in the mouse. Gastroenterology 1985; 88(4):908-12.
164. Sakuma S, Hayashi M, Akashi M. Design of nanoparticles composed of graft copolymers for oral peptide delivery. Adv Drug Deliv Rev 2001; 47(1):21-37.
165. Bai JP, Chang LL, Guo JH. Targeting of peptide and protein drugs to specific sites in the oral route. Crit Rev Ther Drug Carrier Syst 1995; 12(4):339-71.
166. Read NW, Sugden K. Gastrointestinal dynamics and pharmacology for the optimum design of controlled-release oral dosage forms. Crit Rev Ther Drug Carrier Syst 1988; 4(3):221-63.
167. Brown J, Robertson J, Gallagher N. Humoral regulation of vitamin B12 absorption by pregnant mouse small intestine. Gastroenterology 1977; 72(5 Pt 1):881-8.
168. Dew MJ, Hughes PJ, Lee MG, Evans BK, Rhodes J. An oral preparation to release drugs in the human colon. Br J Clin Pharmacol 1982; 14(3):405-8.
169. Saffran M, Kumar GS, Neckers DC, Pena J, Jones RH, Field JB. Biodegradable azopolymer coating for oral delivery of peptide drugs. Biochem Soc Trans 1990; 18(5):752-4.
170. Cheng CL, Gehrke SH, Ritschel WA. Development of an azopolymer based colonic release capsule for delivering proteins/macromolecules. Methods Find Exp Clin Pharmacol 1994; 16(4):271-8.
171. Brondsted H, Kopecek J. Hydrogels for site-specific oral drug delivery: synthesis and characterization. Biomaterials 1991; 12(6):584-92.
172. Brondsted H, Kopecek J. Hydrogels for site-specific drug delivery to the colon: in vitro and in vivo degradation. Pharm Res 1992; 9(12):1540-5.
173. Akala EO, Kopeckova P, Kopecek J. Novel pH-sensitive hydrogels with adjustable swelling kinetics. Biomaterials 1998; 19(11-12):1037-47.
174. Ghandehari H, Kopeckova P, Kopecek J. In vitro degradation of pH-sensitive hydrogels containing aromatic azo bonds. Biomaterials 1997; 18(12):861-72.
175. Bai JP, Chang LL, Guo JH. Effects of polyacrylic polymers on the degradation of insulin and peptide drugs by chymotrypsin and trypsin. J Pharm Pharmacol 1996; 48(1):17-21.
176. Haas J, Lehr CM. Developments in the area of bioadhesive drug delivery systems. Expert Opin Biol Ther 2002; 2(3):287-98.
177. Hussain N, Jani PU, Florence AT. Enhanced oral uptake of tomato lectin-conjugated nanoparticles in the rat. Pharm Res 1997; 14(5):613-8.
178. Bernkop-Schnurch A, Krajicek ME. Mucoadhesive polymers as platforms for peroral peptide delivery and absorption: synthesis and evaluation of different chitosan-EDTA conjugates. J Control Release 1998; 50(1-3):215-23.
179. Wroblewski S, Berenson M, Kopeckova P, Kopecek J. Biorecognition of HPMA copolymer-lectin conjugates as an indicator of differentiation of cell-surface glycoproteins in development, maturation, and diseases of human and rodent gastrointestinal tissues. J Biomed Mater Res 2000; 51(3):329-42.
180. Lu ZR, Gao SQ, Kopeckova P, Kopecek J. Synthesis of bioadhesive lectin-HPMA copolymer-cyclosporin conjugates. Bioconjug Chem 2000; 11(1):3-7.
181. Sicinski P, Rowinski J, Warchol JB, Jarzabek Z, Gut W, Szczygiel B, et al. Poliovirus type 1 enters the human host through intestinal M cells. Gastroenterology 1990; 98(1):56-8.
182. Cornes JS. Number, size and distribution of Peyer's patches in the human small intestine. Gut 1965; 6:225-233.
183. Sackmann W. Number and localization of Peyer's patches in the small intestine of the rabbit (Oryctolagus cuniculus). Acta Anat (Basel) 1977; 97(1):109-13.
184. HogenEsch H, Housman JM, Felsburg PJ. Canine Peyer's patches: macroscopic, light microscopic, scanning electron microscopic and immunohistochemical investigations. Adv Exp Med Biol 1987; 216A:249-56.
185. Kararli TT. Comparison of the gastrointestinal anatomy, physiology, and biochemistry of humans and commonly used laboratory animals. Biopharm Drug Dispos 1995; 16(5):351-80.
186. Reynolds J PR, Bordmann G. In: GGB K, editor. Microenvironments in Lymphoid System. New York: Plenium Press, 1985, 101-109.
187. Schmitz M, Nunez D, Butcher EC. Selective recognition of mucosal lymphoid high endothelium by gut intraepithelial leukocytes. Gastroenterology 1988; 94(3):576-81.
188. Butcher EC, Rouse RV, Coffman RL, Nottenburg CN, Hardy RR, Weissman IL. Surface phenotype of Peyer's patch germinal center cells: implications for the role of germinal centers in B cell differentiation. J Immunol 1982; 129(6):2698-707.
189. Guy-Grand D, Griscelli C, Vassalli P. The gut-associated lymphoid system: nature and properties of the large dividing cells. Eur J Immunol 1974; 4(6):435-43.
190. McWilliams M, Lamm ME, Phillips-Quagliata JM. Surface and intracellular markers of mouse mesenteric and peripheral lymph node and Peyer's patch cells. J Immunol 1974; 113(4):1326-33.
191. Roelants GE, Loor F, von Boehmer H, Sprent J, Hagg LB, Mayor KS, et al. Five types of lymphocytes (Ig-theta-, Ig-theta+weak, Ig-theta+strong, Ig+theta- and Ig+theta+) characterized by double immunofluorescence and electrophoretic mobility. Organ distribution in normal and nude mice. Eur J Immunol 1975; 5(2):127-31.
192. MacDonald TT, Spencer J, Viney JL, Williams CB, Walker-Smith JA. Selective biopsy of human Peyer's patches during ileal endoscopy. Gastroenterology 1987; 93(6):1356-62.
193. Cebra JJ CC, Gearhart PJ, Robertson SM, Tseng J, Watson PM. In: Ogra P DD, editor. Immunology of Breast Milk. New York: Raven Press, 1979, 1-8.
194. Gearhart PJ, Cebra JJ. Differentiated B lymphocytes. Potential to express particular antibody variable and constant regions depends on site of lymphoid tissue and antigen load. J Exp Med 1979; 149(1):216-27.
195. Kiyono H, McGhee JR, Mosteller LM, Eldridge JH, Koopman WJ, Kearney JF, et al. Murine Peyer's patch T cell clones. Characterization of antigen-specific helper T cells for immunoglobulin A responses. J Exp Med 1982; 156(4):1115-30.
196. Kawanishi H, Ozato K, Strober W. The proliferative response of cloned Peyer's patch switch T cells to syngeneic and allogeneic stimuli. J Immunol 1985; 134(6):3586-91.
197. Guy-Grand D, Griscelli C, Vassalli P. The mouse gut T lymphocyte, a novel type of T cell. Nature, origin, and traffic in mice in normal and graft-versus-host conditions. J Exp Med 1978; 148(6):1661-77.
198. Pabst R, Reynolds JD. Peyer's patches export lymphocytes throughout the lymphoid system in sheep. J Immunol 1987; 139(12):3981-5.
199. Binns RM, Pabst R, Licence ST. Lymphocyte emigration from lymph nodes by blood in the pig and efferent lymph in the sheep. Immunology 1985; 54(1):105-11.
200. Mahida YR, Patel S, Jewell DP. Mononuclear phagocyte system of human Peyer's patches: an immunohistochemical study using monoclonal antibodies. Clin Exp Immunol 1989; 75(1):82-6.
201. Egberts HJ, Brinkhoff MG, Mouwen JM, van Dijk JE, Koninkx JF. Biology and pathology of the intestinal M-cell. A review. Vet Q 1985; 7(4):333-6.
202. Wolf JL, Bye WA. The membranous epithelial (M) cell and the mucosal immune system. Annu Rev Med 1984; 35:95-112.
203. Owen RL, Jones AL. Epithelial cell specialization within human Peyer's patches: an ultrastructural study of intestinal lymphoid follicles. Gastroenterology 1974; 66(2):189-203.
204. Inman LR, Cantey JR. Specific adherence of Escherichia coli (strain RDEC-1) to membranous (M) cells of the Peyer's patch in Escherichia coli diarrhea in the rabbit. J Clin Invest 1983; 71(1):1-8.
205. Madara JL, Bye WA, Trier JS. Structural features of and cholesterol distribution in M-cell membranes in guinea pig, rat, and mouse Peyer's patches. Gastroenterology 1984; 87(5):1091-103.
206. Smith MW, Peacock MA. "M" cell distribution in follicle-associated epithelium of mouse Peyer's patch. Am J Anat 1980; 159(2):167-75.
207. Pappo J. Generation and characterization of monoclonal antibodies recognizing follicle epithelial M cells in rabbit gut-associated lymphoid tissues. Cell Immunol 1989; 120(1):31-41.
208. Owen RL, Bhalla DK. Cytochemical analysis of alkaline phosphatase and esterase activities and of lectin-binding and anionic sites in rat and mouse Peyer's patch M cells. Am J Anat 1983; 168(2):199-212.
209. Neutra MR, Phillips TL, Mayer EL, Fishkind DJ. Transport of membrane-bound macromolecules by M cells in follicle-associated epithelium of rabbit Peyer's patch. Cell Tissue Res 1987; 247(3):537-46.
210. Bye WA, Allan CH, Trier JS. Structure, distribution, and origin of M cells in Peyer's patches of mouse ileum. Gastroenterology 1984; 86(5 Pt 1):789-801.
211. Munro HN, Linder MC. Ferritin: structure, biosynthesis, and role in iron metabolism. Physiol Rev 1978; 58(2):317-96.
212. Keljo DJ, Hamilton JR. Quantitative determination of macromolecular transport rate across intestinal Peyer's patches. Am J Physiol 1983; 244(6):G637-44.
213. Owen RL, Apple RT, Bhalla DK. Morphometric and cytochemical analysis of lysosomes in rat Peyer's patch follicle epithelium: their reduction in volume fraction and acid phosphatase content in M cells compared to adjacent enterocytes. Anat Rec 1986; 216(4):521-7.
214. McClugage SG, Low FN, Zimny ML. Porosity of the basement membrane overlying Peyer's patches in rats and monkeys. Gastroenterology 1986; 91(5):1128-33.
215. McClugage SG, Low FN. Microdissection by ultrasonication: porosity of the intestinal epithelial basal lamina. Am J Anat 1984; 171(2):207-16.
216. Rubas W, Banerjea AC, Gallati H, Speiser PP, Joklik WK. Incorporation of the reovirus M cell attachment protein into small unilamellar vesicles: incorporation efficiency and binding capability to L929 cells in vitro. J Microencapsul 1990; 7(3):385-95.
217. Florence AT. The oral absorption of micro- and nanoparticulates: neither exceptional nor unusual. Pharm Res 1997; 14(3):259-66.
218. LeFevre ME, Warren JB, Joel DD. Particles and macrophages in murine Peyer's patches. Exp Cell Biol 1985; 53(3):121-9.
219. Lefevre ME, Joel DD, Schidlovsky G. Retention of ingested latex particles in Peyer's patches of germfree and conventional mice. Proc Soc Exp Biol Med 1985; 179(4):522-8.
220. Hillery AM, Jani PU, Florence AT. Comparative, quantitative study of lymphoid and non-lymphoid uptake of 60 nm polystyrene particles. J Drug Target 1994; 2(2):151-6.
221. Pratten MK, Lloyd JB. Pinocytosis and phagocytosis: the effect of size of a particulate substrate on its mode of capture by rat peritoneal macrophages cultured in vitro. Biochim Biophys Acta 1986; 881(3):307-13.
222. Desai MP, Labhasetwar V, Walter E, Levy RJ, Amidon GL. The mechanism of uptake of biodegradable microparticles in Caco-2 cells is size dependent. Pharm Res 1997; 14(11):1568-73.
223. Joseph JW, Kalitsky J, St-Pierre S, Brubaker PL. Oral delivery of glucagon-like peptide-1 in a modified polymer preparation normalizes basal glycaemia in diabetic db/db mice. Diabetologia 2000; 43(10):1319-28.
224. O'Hagan DT. Novel Delivery Systems for Oral Vaccines. Boca Raton FL: CRC Press, 1994.
225. Guyon-Gruaz A, Delmas A, Pedoussaut S, Halimi H, Milhaud G, Raulais D, et al. Oral immunization with a synthetic peptide of cholera toxin B subunit. Obtention of neutralizing antibodies. Eur J Biochem 1986; 159(3):525-8.
226. Wassef JS, Keren DF, Mailloux JL. Role of M cells in initial antigen uptake and in ulcer formation in the rabbit intestinal loop model of shigellosis. Infect Immun 1989; 57(3):858-63.
227. Michalek SM, Childers NK, Katz J, Denys FR, Berry AK, Eldridge JH, et al. Liposomes as oral adjuvants. Curr Top Microbiol Immunol 1989; 146:51-8.
228. Wolf JL, Rubin DH, Finberg R, Kauffman RS, Sharpe AH, Trier JS, et al. Intestinal M cells: a pathway for entry of reovirus into the host. Science 1981; 212(4493):471-2.
229. Wolf JL, Kauffman RS, Finberg R, Dambrauskas R, Fields BN, Trier JS. Determinants of reovirus interaction with the intestinal M cells and absorptive cells of murine intestine. Gastroenterology 1983; 85(2):291-300.
230. Bassel-Duby R, Jayasuriya A, Chatterjee D, Sonenberg N, Maizel JV Jr, Fields BN. Sequence of reovirus haemagglutinin predicts a coiled-coil structure. Nature 1985; 315(6018):421-3.
231. Lee PW, Hayes EC, Joklik WK. Protein sigma 1 is the reovirus cell attachment protein. Virology 1981; 108(1):156-63.
232. Nagata L, Masri SA, Mah DC, Lee PW. Molecular cloning and sequencing of the reovirus (serotype 3) S1 gene which encodes the viral cell attachment protein sigma 1. Nucleic Acids Res 1984; 12(22):8699-710.
233. Kvietys PR, Wilborn WH, Granger DN. Effects of net transmucosal volume flux on lymph flow in the canine colon. Structural-functional relationship. Gastroenterology 1981; 81(6):1080-90.
234. Kagnoff MF. Immunology of the digestive system. In: Johnson LR, Christensen J, Jackson MJ, Jacobson ED, Walsh JH, editors. Physiology of the Gastrointestinal Tract. New York: Raven Press, 1986, 1699-1728.
235. Alsenz J, Russell-Jones GJ, Westwood S, Levet-Trafit B, de Smidt PC. Oral absorption of peptides through the cobalamin (vitamin B12) pathway in the rat intestine. Pharm Res 2000; 17(7):825-32.
236. Yamamoto A, Taniguchi T, Rikyuu K, Tsuji T, Fujita T, Murakami M, Muranishi S. Effects of various protease inhibitors on the intestinal absorption and degradation of insulin in rats. Pharm Res 1994; 11(10):2496-500.
237. Weltzin R, Lucia-Jandrès P, Michetti P, Fields BN, Kraehenbuhl JP, Neutra MR. Binding and transepithelial transport of immunoglobulins by intestinal M cells: demonstration using monoclonal IgA antibodies against enteric viral proteins. J Cell Biol 1989; 108(5):1673-85.
238. Chen H, Langer RS. Polymerized liposomes to M cells and useful for oral or mucosal drug delivery. US patent 6,060,082, 1997.